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Background: Microincisional vitrectomy surgery (MIVS) is the current standard surgical 
approach for pars plana vitrectomy. Historically, the most common surgical platform for vitrec-
tomy surgery, since its introduction in 1997, has been the Accurus vitrectomy system. Recent 
introduction of the next generation of vitrectomy platforms has generated concerns associated 
with transitioning to new technology in the operating room environment. This study compared, 
in a matched fashion, surgical use of the Accurus vitrectomy system and the next generation 
Constellation Vision System to evaluate surgical efficiencies, complications, and user percep-
tions of this transition.
Methods: Electronic health records were abstracted as a hospital quality assurance activity and 
included all vitreoretinal surgical procedures at the Bascom Palmer Eye Institute, Anne Bates 
Leach Eye Hospital, during two discrete 12-month time periods. These two periods reflected 
dedicated usage of the Accurus (June 2008–May 2009) and Constellation Vision (July 2009–
June 2010) systems. Data were limited to a single surgeon and evaluated for operating room (OR) 
total time usage/day, OR case time/case, and OR surgical time/case. Further analysis evaluated all 
patients undergoing combined MIVS and clear cornea phacoemulsification/intraocular lens (IOL) 
implantation during each individual time period to determine the impact of the instrumentation 
on these parameters. All records were evaluated for intraoperative complications.
Results: Five hundred and fourteen eligible patients underwent MIVS during the 2-year study 
windows, with 281 patients undergoing surgery with the Accurus system and 233 patients under-
going surgery with the Constellation system. Combined MIVS and phacoemulsification with 
IOL implantation was performed 141 times during this period with the Accurus and 158 times 
during the second study period with the Constellation. Total number of patients operated per 
day increased from 7.55 with Accurus to 8.53 with Constellation. Surgical room time decreased 
from 56 minutes with Accurus to 52 minutes with Constellation, and procedure time decreased 
from 35 minutes with Accurus to 31 minutes with Constellation (P , 0.004). Combined MIVS/
phacoemulsification surgery saw similar declines in surgical room time and procedure time 
(P , 0.001). Subset analysis of procedures limited by case number per day (eg, four cases/day, 
five cases/day, six cases/day, and seven or more cases/day) showed similar outcomes with a 
decrease in surgical room time and procedure time. No increases in surgery-related complica-
tions were noted by quality assurance review during these time periods.
Discussion: Transitioning to advanced surgical technology is a complex issue for the surgeon, 
the hospital team, and the hospital administration. This study documents improvement in three 
Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
367
ORIGInAL RESEARCH
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/OPTH.S35603Clinical Ophthalmology 2013:7
significant measures of surgical efficiency: operative number of patients per day, operative room time, and surgical procedure time that 
reflect the positive impact of the novel, combined, integrated, posterior and anterior, ophthalmologic surgical platform of the Constel-
lation Vision System. These data are imperative to evaluate the impact of transition from one surgical platform to another. During this 
transition, hospital quality assurance review and surgeon evaluation of operative complications showed no increased concerns for the shift 
from the Accurus to the Constellation Vision System surgical platform. Further, both operative staff and surgeons felt that the transition 
to the Constellation was not associated with increases in difficulty with setup, turnover, or use and that the Constellation decreased safety 
concerns for surgical usage. Ultimately, in this case, new technology benefited the surgeon, the patient, and the hospital.
Keywords: MIVS, vitrectomy, new technology
Rapid advances in surgical technology have occurred since 
the first automated vitrectomy was performed by Machemer 
in 1971.1,2 From 1971 until 2012, instruments have moved 
from separate systems for vitrectomy cutting, illumination, 
air/fluid exchange, silicone oil injection, automated scissors/
forceps, and operative laser photocoagulation toward inte-
grated platforms that include multiple technologies.3–5
A major advance in technology occurred with the intro-
duction of the Accurus-integrated platform in 1997 (Alcon 
Surgical, Fort Worth, TX, USA). This platform achieved 
enhanced vitrectomy cutter performance, improved surgical 
fluidics, automated silicone oil infusion, and incorporated 
a posterior segment fragmatome and an anterior segment 
phacoemulsification capability. The Accurus platform 
rapidly became the standard within the United States and 
internationally.
By 2008 the Accurus platform was present in over 90% 
of ophthalmologic operating rooms in the United States, 
including both hospital and ambulatory care surgical centers. 
The Accurus platform was characterized by an advanced cut-
ter design, increased cutting rates to 2500 cuts per minute, 
gas-forced fluid infusion, dual halogen light sources, and 
software parameters that were established to maximize cutter 
efficiency at very high cut rates.
At the Bascom Palmer Eye Institute, Anne Bates Leach 
Eye Hospital (BPEI/ABLEH), the Accurus platform became 
the standard vitrectomy console from 1997 to 2008. The 
Vitreoretinal Surgical Service at the BPEI had extensive 
interest in improving surgical platforms and techniques for 
vitreoretinal surgery and actively pursued evaluation and 
acquisition of the next generation vitrectomy platform.
The Constellation Vision System (Alcon Surgical) was 
defined by a marked advance in cutter probe design specifi-
cally for micro-incisional vitrectomy surgery (MIVS), incor-
porating 23- and 25-gauge vitrectomy, markedly increased 
cutting rates to 5000 cuts per minute (enabled by elimination 
of spring technology to re-open the cutter after closure); 
integrated quadruple xenon light sources; had radiofrequency 
identification (RFID) recognition technology for identifying 
the cutter, light pipe, and endolaser probes; improved   cassette 
design to eliminate loss of infusion fluidics; integrated a 
532 nm solid state disc laser; and had torsional anterior seg-
ment phacoemulsification.
This next generation platform addressed many concerns 
for instrument limitation and fluidic compromise associated 
with very high cut rates, while incorporating features that had 
previously required independent stand-alone systems for use 
in complex vitrectomy surgery. Further, specific attention was 
given to the enhanced safety features and targeted platform 
improvements that were designed to increase operating room 
efficiency while improving patient safety; these were attractive 
to our hospital teams and hospital administration.
Prior to evaluation in this study, a transition period was 
established to educate our hospital teams, place the Constel-
lation, establish a disposable supply support, and assist our 
vitreoretinal surgeons. This transition period utilized heavy 
educational support from the Alcon surgical support team 
and from in-house vitreoretinal surgeons aimed at supporting 
our hospital teams, with strong focus on our OR scrub teams 
and our OR circulating nursing teams.
This study was a follow-up to a pre-implementation review 
document that hypothesized reduction in OR turnover times 
that would enable increased surgical volume per vitreoretinal 
surgical room per day. In this study we compared two time 
periods: one in which the Accurus platform was utilized 
exclusively and one in which the Constellation platform was 
utilized exclusively. We evaluated a 12-month time period to 
better minimize potential case mix bias or transition bias and 
to capture a significant case volume for analysis. Use of the 
University of Miami electronic health record enabled broad 
data capture for evaluation of case volume per day, surgical 
room time per case, and surgical procedure time per case. Data 
sets were evaluated blinded to the platform utilized for both the 
Accurus and Constellation Vision System. These data provide 
a foundation for evaluating the selection of novel surgical sys-
tems for the ophthalmic hospital or ambulatory surgical center 
and delineate the impact of transition for critical technology 
required for vitrectomy surgery in the 21st century.
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Methods
A data extract from the BPEI/ABLEH electronic health 
record system, satisfying internal review board requirements, 
was obtained for all surgeries performed by a single surgeon 
(TGM) during two time periods established through the hos-
pital quality assurance program. The first time period, repre-
senting usage of the Accurus platform, was from June 2008 
through May 2009. The second time period, representing 
usage of the Constellation platform, was from July 2009 
through June 2010.
The patient’s electronic health records were then matched 
to BPEI’s billing system to extract the current procedural 
terminology (CPT) codes for each patient encounter. The 
two databases were then combined to form one de-identified 
analytic dataset. The dataset included the following variables: 
claim number, date of service, CPT codes, attending physi-
cian, operating room number, unique patient identifier, patient 
operating room in-time, surgery start time, surgery end time, 
patient operating room out-time.
The operative time data was manually entered into the 
patient electronic health record by the nursing staff on the 
service date as part of their standard operating procedures. 
Total room time was calculated by subtracting the in-room 
time from the out-room time. Total surgery time was calcu-
lated by subtracting the surgery start time from the surgery 
end time. Total surgical day time was calculated from the 
first time in the OR to the last time in the OR for the entire 
surgical day.
We eliminated procedures that could not be performed 
on the two platforms, such as primary scleral buckle, enucle-
ation, or examination under anesthesia. To enhance the evalu-
ation, we evaluated all surgical dates and then surgical dates 
with four, five, six, or greater then/equal to seven cases per 
day. Finally, we eliminated cases that did not include MIVS 
surgery on the surgical day evaluated, such as primary scleral 
buckle, enucleation, or examination under anesthesia.
To evaluate the changes in efficiency between the two 
platforms, we analyzed three metrics: case volume by analyz-
ing patient volume per day, patient throughput by analyzing 
the operating room time, and intra-operative time by analyz-
ing procedure time.
A subset analysis was performed on combination MIVS 
and phacoemulsification surgeries. Combination surgeries 
were defined as surgeries with both an anterior segment and 
a posterior segment procedure coded on the same claim.
We evaluated risk management reporting to detect any 
increase in operative complications, instrument concerns, or 
reported surgical delays. We did not measure the profitability 
or profit margin between the two time periods. Based on 
the staffing model at BPEI, it was determined that staffing 
levels and staff hours remained consistent between the two 
time periods and did not affect any change in throughput 
efficiency.
Statistical analysis utilized a paired t-test (Student’s 
paired t-test, SAS v9.3; SAS, Cary, NC, USA). Statistical 
  significance was established as a P-value less than 0.05 for 
the comparative analysis.
Results
A total of 514 eligible patients identified by evaluation of 
the surgical electronic health records were included in this 
analysis. In the first 12-month study period (Accurus surgi-
cal system), 281 patients underwent vitrectomy surgery with 
141 patients undergoing combined pars plana vitrectomy 
and phacoemulsification/IOL implantation. In the second 
12-month study period (Constellation Vision System), 
233 patients underwent vitrectomy surgery with 158 patients 
undergoing combined pars plana vitrectomy and torsional 
phacoemulsification/IOL implantation (Table 1).
Evaluation of surgical efficiencies documented an increase 
from an average of 7.5 cases per day during the Accurus time 
period to 8.5 cases per day during the   Constellation Vision 
System time period. During these study windows, overall 
surgical time per day decreased during the Constellation 
Vision System time period (Table 1).
Operating room case times averaged 58 minutes during 
the Accurus time period and decreased to 52 minutes during 
the Constellation Vision System time period. Operating room 
Table 1 Overall efficiency review comparing the Accurus to the 
Constellation surgical platform
Accurus  
platform
Constellation  
platform
P-value
MIVS cases 281 233 n/a
MIVS/phaco 141 158 n/a
Surgical patients (per day) 7.55 8.53 P , 0.04
MIVS surgical room time  
(per case, minutes)
56 52 P , 0.01
MIVS surgical case time  
(per case, minutes)
35 31 P , 0.004
MIVS/phaco surgical case  
time (per case, minutes)
43 37 P , 0.001
Notes: Statistically significant increase in number of cases per day (surgical patients), 
decrease in surgical room time, and decrease in surgical procedure time (surgical 
case time). Combined MIVS and phacoemulsification with IOL implantation showed 
greatest improvement in time reduction for Constellation compared with Accurus 
across the entire 2-year cohorts. note sample size of 514 MIVS cases and 299 
combined MIVS/phacoemulsification cases accrued over two 1-year windows.
Abbreviations: MIVS, microincisional vitrectomy surgery; IOL, intraocular lens; 
Phaco, phacoemulsification.
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surgical times averaged 36 minutes during the Accurus time 
period and decreased to 31 minutes during the Constellation 
Vision System time period (P , 0.004) (Tables 1–5).
Finally, operating room surgical times for combined pars 
plana vitrectomy and phacoemulsification with IOL implan-
tation averaged 43 minutes during the Accurus time period 
and decreased to 37 minutes during the Constellation Vision 
System time period (P , 0.001) (Tables 1, 6–9).
Ongoing surgical documentation of intra-operative and 
postoperative complications noted stable complication pro-
files as previously reported.
To determine the potential impact of case volume on 
efficiency evaluation, we correlated all cases and then inde-
pendently evaluated datasets with cutoffs of at least four, 
five, six, or greater than/equal to seven cases per day. This 
analysis showed no statistically significant increased effi-
ciency but clearly suggested a trend to increased efficiency 
with increasing case volume. Clear positive impacts were 
seen for each case volume noting a benefit even for surgical 
volumes as low as four cases per day (unreported analysis 
of a second data set documented improved efficiencies with 
case volumes averaging approximately two cases per day) 
(Tables 2–5).
Statistical analysis noted statistically significant improve-
ments in efficiencies for operative time with both decreased 
procedure and room time associated with transition to the 
Constellation Vision System (P , 0.0004). Additionally, 
for combined MIVS pars plana vitrectomy and torsional 
phacoemulsification/IOL implantation, a marked decrease 
in both procedure and room time were documented 
(P , 0.0001) (Tables 6–9).
Discussion
Vitreoretinal surgical advances have been rapid since the first 
automated vitrectomy surgical units were developed four 
decades ago.6–12 During this period, marked improvements 
in instrument design contributed to significant increases in 
patient safety and improved surgical outcomes. Initially, 
Machemer and others focused on multifunction single-port 
instrumentation, but instrument design continuously evolved 
toward smaller instrument sizes and integrated multiport pars 
plana vitrectomy surgery.1,13–15
Further modifications, from Machemer’s initial vit-
rectomy system1 continued to decrease instrument size, 
ultimately achieving a standard instrument approach with 
20-gauge instruments placed through the sclera in a three-
port pars plana vitrectomy approach whereby one port was 
utilized for infusion, one port for illumination, and one port 
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for the cutter/forceps/scissors. Seeking smaller wounds, more 
rapid wound healing, and elimination of transscleral repeti-
tive instrument passage led to smaller gauge instruments that 
incorporated transconjunctival/transscleral trocars focused on 
23-gauge and 25-gauge surgical instruments.16–20 This MIVS 
approach has rapidly become the current standard with a 
transition from 20-gauge sutured sclerotomies to 23-gauge 
and 25-gauge trocared instrument approaches not requiring 
suture closure. Currently, 27-gauge (and smaller) instruments 
are available and in design.
A major impetus for the development of a novel, advanced, 
integrated platform design has been the surgical requirements 
of increased cutting rates, improved intraocular fluidics, 
enhanced lighting, and deliverable endolaser. This shift to 
small gauge surgery, along with the interest in an integrated 
platform, necessitated the design and development of a novel 
next-generation surgical platform. This ideal platform would 
incorporate very high speed cutting, stable real-time evalua-
tion of intraocular fluidics, markedly improved illumination 
sources, capacity for delivery of high centistoke liquids, 
microvolume deliveries, and integrated laser technology.21–37 
These characteristics define the minimal surgical requirements 
for an integrated platform designed for the 21st century.
Additionally, this study took place during the transition 
from 20-gauge pars plana vitrectomy to 23/25-gauge MIVS. 
This surgical platform transition recognized the initial 
concerns for increased risk of endophthalmitis, choroidal 
detachment, iatrogenic retinal tear and/or detachment, or 
postoperative hypotony associated with microincisional 
vitrectomy.38–42 Focused investigation and training on wound 
construction and surgical technique were instrumental in the 
use of transconjunctival, trocared, nonsutured pars plana 
vitrectomy in the surgical care of our patients. Fortunately, 
these concerns have been alleviated by clinical reviews that 
have not noted increased complication profiles with micro-
incisional vitrectomy.43
In this study, we evaluated the “real world” surgical per-
formance of the platform that has been the “gold standard” 
in vitreoretinal surgical systems, the Accurus platform, and 
contrasted that performance with the next generation vit-
reoretinal platform, the Constellation Vision System.44–48 This 
comparison utilized standard metrics incorporated within the 
BPEI/ABLEH surgical electronic medical record to determine 
case volume per room per day, operating room time per case, 
and surgical time per case along with total operating time per 
room per day. These metrics allow a standardized comparison 
of technologies but require evaluation after a transition window 
when each technology has achieved a steady implementation 
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state of usage. Further, evaluation of a large time frame coupled 
with high surgical numbers, as in this study, eliminates many 
potential biases to evaluation of the utility of new technology, 
such as the Constellation Vision System.
This study documents the increased efficiency of the 
Constellation platform relative to the prior standard Accu-
rus system. The Constellation achieved increased patient 
surgical cases per day by decreasing both operative case 
time and room time. This increase is related to an integrated 
design that facilitates case turnover, vitrectomy instrument 
and cassette setup (and particularly combined vitrectomy/
phacoemulsification instrument setup), and enhancements 
with integrated instrument recognition technology, prepopu-
lated user settings, surgeon-controlled endolaser parameters, 
and rapid priming associated with improved fluidics. These 
platform design changes clearly target improvements for the 
surgeon, the OR team, and the patient.
Ultimately, the decision to transition from existing tech-
nology to new technology should focus first on enhanced 
patient care, including patient safety, improved anatomic 
outcomes, improved visual outcomes, and translation to a 
better quality of life.
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